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Arginine-vasopressin (AVP) and lysine vasopressin (LVP) elicited a dose-dependent inhibition of noradren- 
aline-sensitive cyclic AMP accumulation in rat cerebral cortical slices, and of forskolin-stimulated adenylate 
cyclase activity in a rat cerebral cortical membrane preparation. In both cases LVP was more potent than 
AVP, and exerted half-maximal effects at concentrations imilar to those found effective in binding studies 
on rat hippocampal membranes. In hippocampal slices, AVP did not affect cyclic AMP accumulation at 
low concentrations but potentiated the effect of noradrenaline at higher concentrations. In caudate mem- 
branes, AVP inhibited dopamine-stimulated adenylate cyclase with a similar dose-dependency to that seen 
for forskolin activation in cortex membranes. 
Vasopressin CAMP 
1. INTRODUCTION 
The biochemical actions of vasopressin include 
stimulation of adenylate cyclase in the kidney [l] 
and mobilisation of the phospholipid phosphat- 
idylinositol by a Ca-dependent mechanism in liver 
and aorta [2], these actions providing the bases for 
the antidiuretic and vasopressor effects of the hor- 
mone, respectively. Binding sites for vasopressin 
which are linked to these activities have been found 
in these tissues, and have been designated VZ and 
Vr receptors, respectively [3,4]. In brain, vaso- 
pressin has been shown to affect processes of 
learning and memory, possibly by modulation of 
the activity of the noradrenergic system [5,6]. 
Binding sites for vasopressin with nanomolar af- 
finities have recently been demonstrated in cere- 
bral, particularly hippocampal, tissue [7-91 but 
the relationship of these sites to the physiological 
processes mediated by vasopressin in the brain, 
Abbreviations: AVP, arginine-8-vasopressin; DDAVP, 
I-deamino-[8-D-argininel-vasopressin; IBMX, 3-isobu- 
tyl-1-methylxanthine 
Adenylate cyclase Brain 
and the biochemical mechanisms involved in these 
processes, remain unclear. We have demonstrated 
[lo] that AVP and its derivative DDAVP, which is 
an extremely potent antidiuretic agonist and also 
has marked effects on learning as measured by ex- 
tinction of the conditioned avoidance response 
[ 111, inhibit noradrenalin-sensitive cyclic AMP ac- 
cumulation in slices derived from cortex, caudate 
and hippocampus of rats both in vivo and in vitro. 
An inhibitory effect of vasopressin on adenylate 
cyclase has recently been shown for basal activity 
in human platelets [12] and for forskolin-stimu- 
lated activity in hepatocytes [ 131, although the 
relationship of the inhibition to VI or VZ receptor 
activity is not known. In striatal homogenates [14] 
vasopressin at high (micromolar) concentrations 
was shown to potentiate the stimulatory effect of 
dopamine on adenylate cyclase. Here, the effects 
of various concentrations of AVP and LVP on 
cyclic AMP accumulation induced by noradrena- 
line and forskolin in rat brain slices, and on ade- 
nylate cyclase activity in membrane preparations 
derived from cortex and caudate, have been 
examined. 
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2. MATERIALS AND METHODS 
Male rats of the Sabra strain (150-200 g) were 
used for all experiments. For preparation of slices, 
brain areas were dissected on a cooled dish and 
sliced using a McIlwain tissue chopper set at 
0.35 mm. All slices from each area were prein- 
cubated for 30 min at 37°C in Krebs-Ringer’s 
bicarbonate buffer containing 1.29 mM CaC12, 
gassed with 95% 02 : 5% COZ. The slices were then 
collected on a Buchner funnel and distributed 
among vials containing 5 ml Krebs-Ringer’s with 
additions for 20 min incubation. After this period 
the slices were transferred to test-tubes, centri- 
fuged, the medium decanted, and the pellets 
homogenised in 2 ml (for cortex) or 1 ml (for 
caudate or hippocampus) of 95% ethanol. Ali- 
quots of the supernatants were evaporated to 
dryness under N2 and cyclic AMP determined by 
displacement of [3H]cAMP (Radiochemical Cen- 
tre, Amersham) using a protein binding method 
based on that of Brown et al. [15]. 
For preparation of membranes, brain areas were 
homogenised in 10 vols of 50 mM Tris-HCl (pH 
7.4), 2 mM EGTA, using a Polytron homogeniser, 
and centrifuged at 1000 x g for 10 min. The resul- 
tant supernatant was centrifuged at 20000 x g for 
20 min and the pellet produced washed in the 
original volume of homogenising buffer. It was 
then resuspended to a protein concentration of 
about 1 mg/ml, and 3-ml aliquots stored at 
- 70°C. 
Adenylate cyclase was measured in a total assay 
volume of 0.2 ml in a medium containing 25 mM 
Tris-HCI, 0.5 mM ATP, 2 mM MgCl2, 1 mM 
EGTA, 1.5 mg/ml creatine phosphate, 0.2 mg/ml 
creatine phosphokinase, and 1 mM IBMX. Ex- 
periments involving dopamine stimulation of 
cyclase in caudate membranes were conducted in 
the additional presence of 1 PM GTP. Incubations 
were started by addition of protein and terminated 
after 10 min at 30°C by addition of 0.8 ml ab- 
solute ethanol. The tubes were then centrifuged 
and cyclic AMP in aliquots of the supernatants 
determined as above. 
3. RESULTS 
Incubation of cerebral cortical slices with 50 FM 
noradrenaline led to a 3-fold increase in cyclic 
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Fig-l. Dose-response curve for inhibition of 
noradrenaline-sensitive cyclic AMP accumulation in rat 
cortical slices by AVP and LVP. Basal cyclic AMP levels 
were 17.2 f 2.7 pmol/mg protein and levels in the 
presence of 50pM noradrenaline 49.5 + 4.3 pmol/mg 
protein. Each point represents the mean of 4 separate 
determinations. 
Table 1 
Effects of AVP on hormonal stimulation of cyclic AMP 
formation in hippocampal and caudate preparations 
Preparation 
[AVPI @MI Hippocampal Caudate 
slices membranes 
[stimulating agent: [stimulating agent: 
noradrenaline dopamine 
(50 /WI (50 /WI 
0.7 94 * 20 83 + 8 
14 117 k 23 70 + 9 
55 99 + 17 65 + 5 
110 139 + 16 66 + 6 
220 165 k 35 63 f 7 
550 169 -t 13 45 f 8 
Results are expressed as percentages of values obtained 
in the presence of noradrenaline or of dopamine alone, 
and are mean + SE of 6 observations in each case. Basal 
cyclic AMP levels in hippocampal slices were 10.2 k 
2.2 pmol/mg protein, and levels in the presence of 
50pM noradrenaline 38.1 k 2.5 pmol/mg protein. 
Adenylate cyclase activity in caudate membranes in the 
presence of 1 FM GTP was 35 + 2 pmol/min per mg 
protein, and in the additional presence of 50pM 
dopamine 67 + 5 pmol/min per mg protein 
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Fig.2. Dose-response curve for inhibition of forskolin- 
stimulated adenylate cyclase activity in rat cortical 
membranes by AVP and LVP. Basal adenylate cyclase in 
these membranes was 58 -t 14 pmol/min per mg protein 
and activity in the presence of 50pM forskolin 380 + 
58 pmol/min per mg protein. Each point represents the 
mean of 4 separate determinations. 
AMP content. Addition of increasing concentra- 
tions of AVP to the preparation resulted in a dose- 
dependent inhibition of the response (fig.1). LVP 
in cortical slices was more effective than AVP, and 
produced dose-dependent inhibition of the 
response to noradrenaline with a half-maximally 
effective concentration of 0.3 nM (fig.1). In hip- 
pocampal slices, noradrenaline alone produced a 
4-fold increase in cyclic AMP levels. AVP at low 
concentrations had no effect on this response 
(table l), but at concentrations above 0.2pM ap- 
peared to potentiate the noradrenaline stimulation. 
In a membrane preparation from cerebral cor- 
tex, both AVP and LVP inhibited the stimulation 
of adenylate cyclase activity due to addition of 
5OpM forskolin (fig.2). LVP was again more po- 
tent than AVP and produced half-maximal inhibi- 
tion of the response at a concentration of 7 nM. 
Membranes from caudate nucleus showed a doubl- 
ing of activity when incubated with 50pM 
dopamine. The dopamine stimulation was also 
dose-dependently inhibited by AVP (table 1). In 
hippocampal membranes, AVP did not affect 
either basal or serotonin-stimulated adenylate 
cyclase activity over the entire concentration range 
tested. 
4. DISCUSSION 
The present results show that AVP and LVP at 
concentrations comparable to those used in bind- 
ing studies [3,4,7-91 are capable of inhibiting 
both hormone and forskolin-induced cyclic AMP 
accumulation in preparations of both slices and 
membranes from rat cortex and caudate. Indeed, 
the concentration of AVP giving half-maximal in- 
hibition of noradrenaline-induced cyclic AMP ac- 
cumulation in cortical slices, 3.2 nM, was very 
similar to the Kd determined by Barberis [7] for 
binding of this compound to hippocampal slices, 
2.8 nM. For LVP identical values of 7 nM were 
obtained for half-maximal inhibition of forskolin- 
stimulated adenylate cyclase in cortex membranes 
in the present work, and for binding in hippocam- 
pal membranes. The concentrations found effec- 
tive in this study are greater than the in vivo levels 
of vasopressin in the brain as found by several 
authors [16-181. Hamburger-Bar et al. [16] found 
levels of lo-50 pg/mg protein, corresponding to a 
concentration of l-50 pM, in hippocampus and 
caudate, while the levels in hypothalamus were in 
general lOOO-fold higher. Modulation of the in 
vivo level of vasopressin will therefore result in 
changes in both receptor occupation and the 
degree of inhibition of adenylate cyclase, so that 
both these activities are likely to be involved in the 
physiological effects of the hormone. 
The present results confirm our earlier findings 
]lOl of inhibition by vasopressin of the 
noradrenaline-induced accumulation of cyclic 
AMP in rat cerebral cortex and caudate slices. In 
hippocampal slices, previous results obtained with 
a single concentration of vasopressin [lo] indicated 
no effect in vitro or after acute treatment of 
animals, but inhibition of the noradrenaline 
response after chronic treatment. Church [19] ob- 
tained potentiation of the noradrenaline response 
in mouse hippocampal slices by 1 PM LVP, and 
the present results indicate that a similar 
phenomenon occurs with rat hippocampal slices 
and AVP. In caudate membranes, Courtney and 
Raskind [ 141 observed potentiation of the response 
to dopamine at AVP concentrations of 1 PM and 
above. The present results show that at lower, 
physiological concentrations, AVP inhibits the 
dopamine response, with a concentration 
dependence similar to that seen for inhibition of 
the response to noradrenaline in the cortex slice 
preparation. Inhibition by vasopressin of forskolin 
stimulation of adenylate cyclase has not previously 
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been demonstrated in cerebral preparations, 
although this effect was observed in rat 
hepatocytes [131. 
These results do not permit any definitive con- 
clusions as to whether the effects observed are 
related to VI or VZ receptor function, or whether 
they bear any relation to the actions of vasopressin 
on memory and learning. With regard to the 
former question, values obtained for half-maximal 
inhibition of adenylate cyclase in the present ex- 
periments are similar to those obtained by 
Vanderwel et al. [12], who concluded the effect to 
be mediated by the Vi receptor/Ca2+ mobilisation 
mechanism, in platelets. However, Morgan et al. 
[ 131 observed inhibition of forskolin-stimulated 
adenylate cyclase in hepatocytes with a half- 
maximal response in the same range at 0.1 nM 
even in Ca2+-depleted cells, and concluded that the 
effect does not involve Ca2+ mobilisation. The 
observation that LVP was more potent than AVP 
in these experiments may indeed imply that the ef- 
fect described here is mediated by a third class of 
vasopressin receptors, as has also been proposed 
for the action of vasopressin in stimulating ACTH 
release from the anterior pituitary gland [20]. In- 
creases in cyclic AMP have been proposed to be 
associated with improved performances of animals 
in tests of memory and learning [21], while the ef- 
fects of vasopressin derivatives on learning have 
been considered to be localised to the hippocampus 
[6]. The differential effects of AVP observed in the 
present study in inducing a rise in cyclic AMP ac- 
cumulation in hippocampus, and a fall in the other 
brain areas tested, may therefore be relevant to 
molecular processes underlying learning and 
memory phenomena. Further work to resolve these 
questions is in progress. 
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